E4CPG (3-30 nmol/site (i.t.), 1-10 μmol/paw (i.pl.), and 1-10 nmol/site (i.c.v.)) significantly inhibits the nociception induced by the Glutamate-injection (i.pl.; 30 μmol/paw), and the maximal inhibition values for the antinociceptive action of E4CPG in Glutamate-induced nociception are 48% (i.pl.), 49% (i.t.) and 40% (i.c.v.) [4].
E4CPG (35 nM/3.5 μL, i.c.v.) completely blocks long-term depression (LTD) induced by the group I mGluR agonist Dihydroxyphenylglycine (DHPG, 100 nM/5 μL, i.c.v.) in male Sprague-Dawley rats[5].
| Animal Model: | Male Swiss mice (25-35 g)[4] |
| Dosage: | 3-30 nmol/site (i.t.), 1-10 μmol/paw (i.pl.) and 1-10 nmol/ site (i.c.v.)
|
| Administration: | Single injection |
| Result: | The maximal inhibition values for the antinociceptive action of E4CPG in glutamate-induced
nociception were 48% (i.pl.), 49% (i.t.) and 40% (i.c.v.).
|
| Animal Model: | Male Sprague-Dawley rats[5] |
| Dosage: | 35 nM/3.5 μL |
| Administration: | Single injection, i.c.v. |
| Result: | Completely blocked LTD induced by the group I mGluR agonist dihydroxyphenylglycine (DHPG). |
